Neuroprotective Effects of Creatine and Cyclocreatine in Animal Models of Huntington’s Disease

Russell T. Matthews,1 Lichuan Yang,1 Bruce G. Jenkins,1 Robert J. Ferrante,2 Bruce R. Rosen,1 Rima Kaddurah-Daouk3 and M. Flint Beal1

1Neurochemistry Laboratory, Neurology Service and Massachusetts General Hospital Nuclear Magnetic Resonance Center, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, 2Geriatric Research Educational and Clinical Center, Bedford Veterans Administration Medical Center, Department of Neurology and Pathology, Boston University School of Medicine, Boston, Massachusetts 02115, and 3The Avicena Group, Inc., Cambridge, Massachusetts 02139

The gene defect in Huntington’s disease (HD) may result in an impairment of energy metabolism. Malonate and 3-nitropropionic acid (3-NP) are inhibitors of succinate dehydrogenase that produce energy depletion and lesions that closely resemble those of HD. Oral supplementation with creatine or cyclocreatine, which are substrates for the enzyme creatine kinase, may increase phosphocreatine (PCr) or phosphocreatine (PCCr) levels and ATP generation and thereby may exert neuroprotective effects. We found that oral supplementation with either creatine or cyclocreatine produced significant protection against malonate lesions, and that creatine but not cyclocreatine supplementation significantly protected against 3-NP neurotoxicity. Creatine and cyclocreatine increased brain concentrations of PCr and PCCr, respectively, and creatine protected against depletions of PCr and ATP produced by 3-NP. Creatine supplementation protected against 3-NP induced increases in striatal lactate concentrations in vivo as assessed by 1H magnetic resonance spectroscopy. Creatine and cyclocreatine protected against malonate-induced increases in the conversion of salicylate to 2,3- and 2,5-dihydroxybenzoic acid, biochemical markers of hydroxyl radical generation. Creatine administration protected against 3-NP-induced increases in 3-nitrotyrosine concentrations, a marker of peroxynitrite-mediated oxidative injury. Oral supplementation with creatine or cyclocreatine results in neuroprotective effects in vivo, which may represent a novel therapeutic strategy for HD and other neurodegenerative diseases.

Key words: creatine; ATP; oxidative injury; 3-nitrotyrosine; 3-nitropropionic acid; Huntington

There is substantial evidence that impairment of energy production may play a role in the pathogenesis of neurodegenerative diseases (Albin and Greenamyre, 1992; Beal, 1992). Impaired energy production may lead to activation of excitatory amino acid receptors, increases in intracellular calcium, and the generation of free radicals (Beal, 1995). In Huntington’s disease (HD) there is reduced mitochondrial complex II–III activity in postmortem tissue (Gu et al., 1996; Browne et al., 1997) and increased cerebral lactate concentrations in vivo (Jenkins et al., 1993). Animal models of Huntington’s disease involve deficits in energy production. Malonate and 3-nitropropionic acid are, respectively, reversible and irreversible inhibitors of mitochondrial complex II (succinate dehydrogenase), which produce striatal lesions similar to those of HD (Beal et al., 1993b; Greene et al., 1993; Brouillet et al., 1995). The pathogenesis of lesions produced by these compounds involves energy depletion, followed by activation of excitatory amino acid receptors and free radical production (Schulz et al., 1995a,b). The ensuing cell death involves both apoptosis and necrosis (Pang and Geddes, 1997; Sato et al., 1997).

Creatine kinase (CK) is a key enzyme involved in regulating energy metabolism in cells with intermittently high and fluctuating energy requirements, including the brain (Chen et al., 1995). The enzyme catalyzes the reversible transfer of the phosphoryl group from phosphocreatine (PCr) to ADP to generate ATP (for review, see Wallimann, 1992). Several cytoplasmic and mitochondrial isoforms have been identified, which along with the substrates creatine and PCr constitute an intricate cellular energy buffering and transport system, connecting sites of energy production with sites of energy consumption (Hemmer and Wallimann, 1993).

The mitochondrial isoform of creatine kinase (Mi-CK) is located at contact sites between the inner and outer membranes, where it is associated with porin (Wallimann et al., 1992; Brdiczka et al., 1994). Mi-CK can convert intramitochondrially produced ATP to ADP directly, which then gets transported to sites of energy consumption. The mitochondrial isoform is also coupled to oxidative phosphorylation via the adenine nucleotide translocator, and a functional coupling between the isoenzyme and porin has been postulated (Hemmer and Wallimann, 1993). A complex between porin and the adenine nucleotide translocator appears to play a role in the mitochondrial permeability transition, which is linked to both apoptotic and necrotic cell death (Beutner et al., 1997).

If energy impairment plays a critical role in the aforementioned animal models of Huntington’s disease, then compounds that increase the cerebral energy reserve might be neuroprotective. Both creatine and cyclocreatine are substrates for mitochondrial creatine kinase and have been shown to modulate rates of ATP
production (Boehm et al., 1996). Cyclocreatine is the most kinetically active analog of creatine in the CK reaction, leading to formation of phosphorylcreatine (PCCr). We therefore examined whether oral administration of either creatine or cyclocreatine could exert neuroprotective effects against malonate and 3-nitropropionic acid neurotoxicity. We also examined the ability of creatine and cyclocreatine to buffer malonate-induced ATP depletions and whether neuroprotective effects correlated with reduced free radical generation.

**MATERIALS AND METHODS**

We initially examined whether oral administration of creatine or its analog cyclocreatine could attenuate malonate lesions. Male Sprague Dawley rats (Charles River, Cambridge, MA) weighing 300–325 gm were used. Malonate, 3-nitrotyrosine, creatine, and 2,3- and 2,5-dihydroxybenzoic acid (DHBA) were obtained from Sigma (St. Louis, MO). Cyclocreatine was supplied by the Avicenna Group and was synthesized as reported previously (Roberts and Walker, 1982). Creatine was administered orally to rats in their feed at doses of 0.25–3% in the diet. Cyclocreatine was administered at 0.25–1.0%. Controls received unsupplemented but otherwise identical diets. The compounds were administered for 2 weeks before intrastriatal administration of malonate and saline. Malonate was suspended in 2 ml distilled, deionized water, and the pH was adjusted to 7.4 with 0.1 M HCl. Intrastriatal injections of 1.5 μl of malonate containing 3 μmol were made with a 10 μl Hamilton syringe fitted with a 26 gauge blunt-tipped needle, into the left striatum at the level of the bregma, 2.4 mm lateral to the midline, and 4.5 mm ventral to the dura as described previously. Animals were killed at 7 d after injection, and the brains were quickly removed and placed in ice-cold 0.9% saline solution. Brains were sectioned at 2 mm intervals. Slices were then placed posterior side down in 2% 2,3,5-triphénylterazolium chloride (TTC). Slices were stained in the dark at room temperature for 30 min and then removed and placed in 4% paraformaldehyde, pH 7.3. Lesions, noted by pale staining, were evaluated on the posterior surface of each section using a Bioquant 4 system by an experienced histologist blinded to experimental conditions. These measurements have been validated by comparing them with measurements obtained on adjacent Nissl-stained sections (Schulz et al., 1995a).

Creatine or cyclocreatine was administered orally at a dose of 1% in feed to animals treated with 3-nitropropionic acid (3-NP). Controls received unsupplemented rat chow. 3-NP was diluted in water and adjusted to pH 7.4 with NaOH and administered at a dose of 10 mg/kg intraperitoneally every 12 hr for 9–11 d. Because of variability in the times at which animals became ill, animals were examined clinically 3 hr after the injections, and when an animal was acutely ill one animal from each group was killed, regardless they were examined clinically 3 hr after the injections, and when an animal was acutely ill one animal from each group was killed, regardless of whether it was on a control diet or a creatine-supplemented diet (Schulz et al., 1995a). Nine to 10 animals were examined in each group. Animals were examined after showing signs of illness, and striatal tissue was dissected on a freezing cold plate (−20°C) and placed in 0.4 M perchloric acid. Samples were subsequently sonicated, frozen, and centrifuged twice. An aliquot of supernatant was stored at −80°C until injected. Standards were prepared in 0.4 M perchloric acid at concentrations of 10 μM for creatine, cyclocreatine, PCr, and IMP, 5 μM for NAD, ADP, and ATP, and 200 μM for lactate (based on tissue concentrations). Samples were separated on a 15 cm 3 μM Nikko Bioscience C18 HPLC column (ESA, Inc., Chelmsford, MA) at a flow rate of 1 ml/min using a gradient. Buffer A was 25 mM Na2HPO4 with 100 mM tetrabutylammonium (TBA), pH 5.5, whereas buffer B was 200 mM NaH2PO4 with 100 mM TBA, pH 4.0, and 10% acetonitrile. The gradient was 100% buffer A for 0–5 min, 100% buffer B to 100% buffer B for 5–25 min, and 100% buffer B for 25–34 min. Samples were monitored at 241 nm for δ-9 min, 260 nm for 9–25 min, and 214 nm for 25–34 min. The retention times were (in min): creatine, −1.8; cyclocreatine, −2.0; lactate, −3.1; PCr (PCCr), −5.4; IMP, −13.8; GDP, −17.2; AMP, −18.4; NAD, −19.0; ADP-GTP, −21.0; and ATP, −23.4. The ADP and GTP peaks did not resolve, and the combined peak was calculated using the ADP standard. All standards were linear over a 100-fold concentration range.

The salicylate hydroxyl radical-trapping method was used for measuring levels of hydroxy radicals in striatal tissue after malonate injections. Eight animals in each group were fed either a normal diet, a 1% creatine-supplemented diet, or a 1% cyclocreatine-supplemented diet for 2 weeks before intrastriatal malonate, as described above. Animals were injected with 200 mg/kg salicylate intraperitoneally just before the malonate injections and were killed 1 hr later. The striata were then dissected rapidly from a 2-mm-thick slice and placed in 0.25 ml of chilled 0.1 M perchloric acid. Samples were subsequently sonicated, frozen rapidly and thawed, and centrifuged twice. An aliquot of supernatant was analyzed by HPLC with 16-electrode electrochemical detection (Beal et al., 1990). Salicylate, 2,3- and 2,5-DHBA, tyrosine, and 3-nitrotyrosine were measured electrochemically by oxidation at 840, 240, 120, 600, and 840 mV, respectively, with retention times of 20.5, 9.4, 6.3, 10.5, and 18.2 min, respectively. The data were expressed as the ratio of 2,3- and 2,5-DHBA to salicylate to normalize the DHBA concentrations for differing brain concentrations of salicylate. Similarly, 3-nitrotyrosine levels were normalized to tyrosine levels. We also examined the effects of 1% creatine supplementation for 2 weeks on 3-NP-induced increases in 3-nitrotyrosine levels. Male Sprague Dawley rats were treated with 3-NP at a dose of 20 mg/kg intraperitoneally and then killed at 3 hr. Ten animals were examined in each group. The striata were dissected and weighed, and 0.1 M perchloric acid, 3-Nitrotyrosine and tyrosine concentrations were measured by HPLC with electrochemical detection as above.

Statistical comparisons were made by unpaired Student’s t test or by one-way ANOVA followed by Fisher’s protected least significant difference test for post hoc comparisons.
RESULTS

In initial pilot experiments we found that oral supplementation with both creatine and cyclocreatine protected against striatal malonate lesions. We then examined a dose–response curve for neuroprotection of both creatine and cyclocreatine against malonate-induced striatal lesions. As shown in Figure 1, increasing doses of creatine from 0.25 to 3% administered for 2 weeks in the diet exerted dose-dependent neuroprotective effects against malonate-induced striatal lesions. Significant protection occurred with doses of 1 and 2% in the diet. There was less protection at 3% creatine, suggesting that a U-shaped dose response may occur with higher doses. Administration of cyclocreatine resulted in dose-dependent neuroprotective effects, which were significant at a dose of 1% cyclocreatine.

We examined the effects of both creatine and cyclocreatine on subacute 3-NP neurotoxicity. Dietary supplementation with 1% creatine for 2 weeks resulted in a significant 83% reduction in lesion volume produced by 3-NP (Fig. 2). In contrast, animals treated with cyclocreatine became ill earlier and appeared to have an exacerbation of toxicity (data not shown). This striking neuroprotection was histopathologically confirmed using Nissl stains (Fig. 3). Lesions could not be detected in the creatine-fed animals, whereas the mean lesion volumes in the 3-NP-treated animals on control diets were 19.7 ± 5.1 mm³.

We investigated the mechanism of neuroprotection of creatine against malonate and 3-NP-induced neurotoxicity. We examined whether creatine can increase brain energy reserves and can prevent depletions of high-energy phosphate compounds induced by 3-NP. We measured creatine, lactate, PCr, GDP, AMP, NAD, ADP–GTP, and ATP levels after oral administration of 1% creatine (column 2) or 1% cyclocreatine (column 3) for 2 weeks compared with an unsupplemented diet (control) (Table 1). The ADP–GTP peak did not resolve the two compounds and therefore reflects a combination of both. Creatine administration produced a significant increase in striatal PCr levels. Cyclocreatine resulted in significant reductions in creatine, which has been noted previously, presumably because of its own buildup in the brain. Cyclocreatine was phosphorylated efficiently by creatine kinase to yield PCCr, which builds up to levels almost 20-fold greater than PCr levels. Administration of 3-NP in controls (column 4) produced a significant decrease in striatal concentrations of creatine, PCr, GDP, AMP, NAD, ADP–GTP, and ATP, whereas there was a significant increase in lactate. The reductions in Cr, PCr, GDP, AMP, NAD, ADP–GTP, and ATP and the increase in lactate were attenuated significantly in animals fed for 2 weeks with 1% creatine (column 5).

We also investigated the effects of creatine feeding on increases in striatal lactate concentrations induced by 3-NP in vivo using 1H magnetic resonance spectroscopy. Animals were fed with 1% creatine for 2 weeks before intravenous administration of 3-NP at a dose of 33 mg/kg. We adopted this route of administration because it resulted in more reproducible increases in lactate. As shown in Figure 4, there was a significant reduction in lactate/ NAA ratios in animals fed with creatine. Representative chemical shift spectra are shown in Figure 5. The effects of feeding 1% cyclocreatine on PCr and ATP levels were assessed by phosphorus magnetic resonance spectroscopy. Relative concentrations were calculated compared with external standards. We examined six animals fed with cyclocreatine and nine controls. Animals fed with cyclocreatine showed increases in ATP levels from 0.076 ± 0.009 at baseline to 0.115 ± 0.098 at 2–6 weeks (p < 0.05) and increases in PCr and PCCr from 0.057 ± 0.008 at baseline to 0.137 ± 0.098 at 2–6 weeks (p < 0.05).

A consequence of energy impairment produced by either malonate or 3-NP is the generation of free radicals, which appear to play a role in cell death, because both free radical scavengers and nitric oxide synthase inhibitors can attenuate the toxicity produced by either compound significantly (Greenamyre et al., 1994; Schulz et al., 1995a,b, 1996). In the present experiments we investigated the effects of oral administration of either 1% creatine or 1% cyclocreatine for 2 weeks on malonate-induced increases in DHBA/salicylate and 3-nitrotyrosine/tyrosine. Animals were killed 1 hr after the malonate injection. As shown in Figure 6, malonate produced significant increases in both 2,3- and 2,5-DHBA/salicylate, which were significantly attenuated in animals fed with either creatine or cyclocreatine. A significant increase in 3-nitrotyrosine/tyrosine was found in control animals, but smaller increases in 3-nitrotyrosine/tyrosine in the creatine- and cyclocreatine-fed animals did not reach significance. We also examined the effects of 1% creatine feeding for 2 weeks on...
increases in 3-nitrotyrosine/tyrosine levels produced by 20 mg/kg 3-NP at 3 hr after administration. As shown in Figure 7, increases in 3-nitrotyrosine/tyrosine were significantly decreased in the creatine-fed animals.

**DISCUSSION**

There is substantial evidence that a secondary consequence of the gene defect in HD may be an impairment of energy metabolism. HD patients show weight loss despite a normal or increased caloric intake (O’Brien et al., 1990). Furthermore, we showed increased lactate concentrations in both the striatum and cerebral cortex of HD patients, as assessed using $^1$H magnetic resonance spectroscopy (Jenkins et al., 1993). We recently found a reduced PCr/Pi ratio in resting gastrocnemius muscle of HD patients (Koroshetz et al., 1997). In postmortem brain tissue there is decreased complex II–III activity in HD basal ganglia (Gu et al., 1996; Browne et al., 1997).

We and others found that intrastriatal injections of the reversible succinate dehydrogenase inhibitor malonate or systemic administration of the irreversible succinate dehydrogenase inhibitor

Table 1. Striatal energy metabolites in creatine- and cyclocreatine-fed animals (μmol/gm wet weight)

<table>
<thead>
<tr>
<th>Metabolite</th>
<th>Control</th>
<th>Creatine</th>
<th>Cyclocreatine</th>
<th>Control with 3-NP</th>
<th>Creatine with 3-NP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Creatine</td>
<td>9.07 ± 0.52</td>
<td>9.68 ± 0.43</td>
<td>5.60 ± 0.09*</td>
<td>4.91 ± 0.76*</td>
<td>7.88 ± 0.61**</td>
</tr>
<tr>
<td>Lactate</td>
<td>3.08 ± 0.51</td>
<td>2.72 ± 0.33</td>
<td>3.40 ± 0.62</td>
<td>14.05 ± 3.02**</td>
<td>8.75 ± 2.14***</td>
</tr>
<tr>
<td>PCr, PCCr</td>
<td>1.64 ± 0.20</td>
<td>2.70 ± 0.29*</td>
<td>53.5 ± 2.5*</td>
<td>0.62 ± 0.16****</td>
<td>1.14 ± 0.17***</td>
</tr>
<tr>
<td>GDP</td>
<td>0.23 ± 0.02</td>
<td>0.24 ± 0.02</td>
<td>0.21 ± 0.01</td>
<td>0.07 ± 0.01*</td>
<td>0.17 ± 0.02**</td>
</tr>
<tr>
<td>AMP</td>
<td>0.91 ± 0.08</td>
<td>0.96 ± 0.06</td>
<td>0.79 ± 0.02</td>
<td>0.35 ± 0.06*</td>
<td>0.65 ± 0.12*****</td>
</tr>
<tr>
<td>NAD</td>
<td>1.06 ± 0.07</td>
<td>0.97 ± 0.05</td>
<td>0.91 ± 0.03</td>
<td>0.41 ± 0.09*</td>
<td>1.01 ± 0.14**</td>
</tr>
<tr>
<td>ADP–GTP</td>
<td>0.71 ± 0.03</td>
<td>0.79 ± 0.04</td>
<td>0.77 ± 0.02</td>
<td>0.23 ± 0.05*</td>
<td>0.64 ± 0.07**</td>
</tr>
<tr>
<td>ATP</td>
<td>1.23 ± 0.18</td>
<td>1.38 ± 0.17</td>
<td>1.50 ± 0.10</td>
<td>0.31 ± 0.10*</td>
<td>0.99 ± 0.19*****</td>
</tr>
</tbody>
</table>

$n = 8–10$ animals per group.

*Values are PCr, except for after feeding with cyclocreatine, when they are PCCr.

* $P < 0.001$; **** $P < 0.01$ compared with control.

** $P < 0.001$; *** $P < 0.05$; ***** $P < 0.01$ compared with control with 3-NP.

Figure 3. Nissl and NADPH–diaphorase double-stained coronal brain sections at the level of the striatum and anterior commissure from a creatine-fed rat (A, C) and a non-creatine-fed rat (B, D). Rats prefed 1% creatine with subsequent administration of 3-nitropropionic acid resulted in no demonstrable striatal lesions (A) or neuronal loss or alteration (C). In contrast, treatment with 3-nitropropionic acid alone resulted in bilateral striatal lesions within the caudate–putamen (arrows) (B) with marked neuronal loss and relative preservation of NADPH-diaphorase neurons (dark-stained neurons) (D). Note the ventricular enlargement attributable to striatal atrophy in the 3-nitropropionic acid-treated rat.
3-nitropropionic acid results in striatal lesions that closely mimic HD neuropathology (Beal et al., 1993a,b; Greene et al., 1993; Brouillet et al., 1995). There is sparing of striatal afferents and striatal NADPH–diaphorase interneurons, with a depletion of striatal projection neurons. In primates systemic administration of 3-NP produces the characteristic histopathological features of HD, as well as both a choreiform movement disorders and frontal-type cognitive deficits, which are typical clinical manifestations of HD (Brouillet et al., 1995; Palfi et al., 1996).

Both malonate and 3-NP produce energy defects in vivo, followed by activation of excitatory amino acid receptors and the generation of free radicals (Beal et al., 1993a,b; Greene et al., 1993; Greenamyre et al., 1994; Schulz et al., 1995a,b). If the initiating step in the pathological cascade is a depletion of cellular energy stores, then agents that can buffer cellular energy stores may be neuroprotective. The brain isoform of creatine kinase, along with the mitochondrial isoform and the substances Cr and PCr, constitute a system that seems to be critical in regulating energy homeostasis in the brain and other organs with high and fluctuating energy demands (Hemmer and Wallimann, 1993). The mitochondrial isoform is part of a complex of proteins that form an efficient, tightly coupled multienzyme energy channel, which generates and transports energy in the form of PCr, from the mitochondrial matrix to the cytoplasm. Creatine is an excellent stimulant for mitochondrial respiration, resulting in the generation of PCr (Kernec et al., 1996; O’Gorman et al., 1996).

Substantial evidence supports a direct functional coupling of creatine kinase with Na$$^+$$/K$$^+$$ ATPase, neurotransmitter release, and in maintenance of membrane potentials and restoration of ion gradients before and after depolarization (Dunant et al.,...
High-energy turnover and high creatine kinase concentrations have been found in those regions of the brain that are rich in synaptic connections, e.g., the molecular layer of the cerebellum, glomerular structures of the granule layer, and the hippocampus (Kaldis et al., 1996). An important role of creatine kinase in the adult brain is supported by in vivo $^{31}$P NMR transfer measurements showing the pseudo-first-order rate constant of the creatine kinase reaction (in the direction of ATP synthesis) (Corbett and Laptook, 1994). Creatine kinase flux correlates with brain activity, as measured by EEG, as well as the amount of 2-deoxyglucose phosphate found in the brain (Sauter and Rudin, 1993).

A novel strategy to improve brain energy stores is therefore to administer either creatine or an analog such as cyclocreatine, which leads to high-energy phosphagens and which potentially could sustain ATP production by the creatine kinase reaction. Previous studies in both the heart and skeletal muscle showed that cyclocreatine administration resulted in increased tissue levels of cyclocreatine and phosphocyclocreatine, delayed depletion of ATP levels under ischemic conditions, and delayed onset of ischemia-induced rigor (Griffiths and Walker, 1976; Annesley and Walker, 1980; Roberts and Walker, 1982; Turner and Walker, 1987; Elgebaly et al., 1994). Creatine had no effect on ischemia-induced ATP depletion in the heart, but it did protect against ATP depletion produced by arterial hypertension (Turner and Walker, 1985; Osbakken et al., 1992; Constantin-Teodosiu et al., 1995). In hippocampal slices creatine supplementation increased PCr levels, delayed synaptic failure, and ameliorated neuronal damage produced by anoxia (Whittingham and Lipton, 1981; Carter et al., 1995). Cyclocreatine administration in vivo increased brain concentrations of PCCr and appeared to buffer ATP stores (Woznicki and Walker, 1980).

In the present study we found that oral administration of both creatine and cyclocreatine produced dose-dependent neuroprotective effects against malonate lesions. The protection with creatine was diminished at the highest dose level, suggesting that there may be a U-shaped dose response at higher doses. We observed similar effects with MPTP-induced dopamine depletions (M. F. Beal et al., unpublished data). The best neuroprotection was that seen after subacute administration of 3-NP. A significant 83% reduction in lesion volume was observed in animals fed 1% creatine.

The mechanism of neuroprotection involves protection against depletions of both PCr and ATP. We found that administration of either creatine or cyclocreatine results in increased brain concentrations of PCr or PCCr, respectively. There was a trend toward increased ATP, as determined biochemically and by magnetic resonance spectroscopy. Increases in ATP levels are somewhat unexpected, because brain ATP levels are thought to be regulated tightly (Erecinska and Silver, 1989). Administration of 3-NP produced significant decreases in creatine, PCr, GDP, AMP, NAD, ADP–GTP, and ATP. These energy metabolites are also decreased by cerebral ischemia (Lazzarino et al., 1992) and by
3-NP in vitro (Erecinska and Nelson, 1994) and in vivo (Brouillet et al., 1993; Tsi et al., 1997). Creatine administration significantly protected against the decreases. Furthermore, creatine administration protected against 3-NP-induced increases of lactate, as assessed by $^1$H magnetic resonance spectroscopy in vivo. These findings therefore provide the first in vivo data that creatine administration can increase brain high-energy phosphate compounds and can protect against energy compromise produced by mitochondrial toxins. Decreases in NAD and ATP may be a consequence of both impaired mitochondrial function as well as activation of poly-ADP-ribose polymerase, which plays a role in neuronal cell death in vitro (Zhang et al., 1994). The ability of Pcr to stimulate synaptic gamping uptake and thereby to reduce extracellular glutamate may also play a role in the neuroprotective effects of creatine and cyclocreatine (Xu et al., 1996).

A secondary consequence of energy impairment is increased intracellular concentrations of calcium attributable to both impaired mitochondrial calcium buffering and activation of voltage-dependent NMDA excitatory amino acid receptors (Beal, 1992, 1995). This leads to increased free radical production by mitochondria as well as activation of neuronal nitric oxide synthase, which is calmodulin-dependent. This can lead to the generation of peroxynitrite, formed by the interaction of O$_2^*$ with NO$. Peroxynitrite can oxidize an intracellular molecule by a “hydroxyl radical”-like activity, and it also can lead to nitration of tyrosines (Beckman et al., 1990, 1992). We showed previously that both malonate and 3-NP result in increases in both hydroxyl radical activity, as well as 3-nitrotyrosine (Shulz et al., 1995a,b). Furthermore, both free radical scavengers and nitric oxide synthase inhibitors can attenuate both malonate and 3-NP neurotoxicity (Greenamyre et al., 1994; Schulz et al., 1995a,b, 1996).

Creatine kinase appears to be coupled directly or indirectly to energetic processes required for calcium homeostasis (Wallimann et al., 1992; Steeghs et al., 1997). Creatine pretreatment delayed increases in intracellular calcium produced by 3-NP in cortical and striatal astrocytes in vitro (Descphane et al., 1997). Administration of creatine or cyclocreatine therefore may improve intracellular calcium buffering and may prevent free radical production by mitochondria. In the present experiments we found that administration of both creatine and cyclocreatine significantly attenuated malonate-induced increases in 2,3- and 2,5-DHBA/salicylate, markers of hydroxyl radical generation (Floyd et al., 1984). Increased 3-nitrotyrosine levels after malonate were significantly attenuated. Oral administration of creatine reduced 3-NP-induced increases in 3-nitrotyrosine significantly. These findings therefore suggest that improved energy buffering can act upstream to attenuate free radical generation, which is associated with cell death produced by mitochondrial toxins.

The present studies demonstrate that oral administration of either creatine or cyclocreatine can buffer cellular ATP concentrations and can attenuate cell death in animal models that mimic the neuropathological and clinical phenotype of HD. By attenuating ATP depletion these compounds appear to prevent a pathological cascade, which leads to free radical generation and eventual cell death. Creatine administration is well tolerated in man and may have benefits in pathological conditions (Balsom et al., 1994; Dawson et al., 1995). Long-term administration to patients with gyrate atrophy of the choroid and retina prevented visual field constriction and resulted in improvement of muscle biopsy findings (Sipila et al., 1981). A pediatric patient with creatine deficiency in brain accompanied by an extrapyramidal movement disorder showed partial restoration of cerebral creatine concentrations and clinical improvement with oral creatine administration (Stockler et al., 1994, 1996). Creatine administration resulted in improvement in a patient with the mitochondrial disorder mitochondrial encephalopathy lactic acidosis and strokes (Hagenfeldt et al., 1994). The present findings suggest that treatment with creatine or its analogs might be a novel therapeutic strategy to slow or halt neurodegeneration in HD. Similar strategies might be effective in other neurodegenerative diseases in which defects in energy metabolism are implicated (Beal, 1992).

REFERENCES


Beckmann JS, Beckman TW, Chen J, Marshall PA, Freeman BA (1990) Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 87:1620–1624.


